Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test

Edoardo G. Giannini, Federica Malfatti, Federica Botta, Simone Polegato, Emanuela Testa, Alessandra Fumagalli, Mario Mamone, Vincenzo Savarino, Roberto Testa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.

Original languageEnglish
Pages (from-to)1207-1213
Number of pages7
JournalDigestive Diseases and Sciences
Volume50
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Rabeprazole
Aminopyrine
Breath Tests
Clarithromycin
Metronidazole
Helicobacter pylori
Cytochrome P-450 Enzyme System
Pharmaceutical Preparations
Liver
Therapeutics
Helicobacter Infections
Drug Interactions

Keywords

  • C-aminopyrine breath test
  • Clarithromycin
  • Helicobacter pylori
  • Liver function
  • Metronidazole
  • Rabeprazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. / Giannini, Edoardo G.; Malfatti, Federica; Botta, Federica; Polegato, Simone; Testa, Emanuela; Fumagalli, Alessandra; Mamone, Mario; Savarino, Vincenzo; Testa, Roberto.

In: Digestive Diseases and Sciences, Vol. 50, No. 7, 07.2005, p. 1207-1213.

Research output: Contribution to journalArticle

Giannini, Edoardo G. ; Malfatti, Federica ; Botta, Federica ; Polegato, Simone ; Testa, Emanuela ; Fumagalli, Alessandra ; Mamone, Mario ; Savarino, Vincenzo ; Testa, Roberto. / Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. In: Digestive Diseases and Sciences. 2005 ; Vol. 50, No. 7. pp. 1207-1213.
@article{6d15d23f08d2406eb1738c7e530e9cb6,
title = "Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test",
abstract = "Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.",
keywords = "C-aminopyrine breath test, Clarithromycin, Helicobacter pylori, Liver function, Metronidazole, Rabeprazole",
author = "Giannini, {Edoardo G.} and Federica Malfatti and Federica Botta and Simone Polegato and Emanuela Testa and Alessandra Fumagalli and Mario Mamone and Vincenzo Savarino and Roberto Testa",
year = "2005",
month = "7",
doi = "10.1007/s10620-005-2761-z",
language = "English",
volume = "50",
pages = "1207--1213",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test

AU - Giannini, Edoardo G.

AU - Malfatti, Federica

AU - Botta, Federica

AU - Polegato, Simone

AU - Testa, Emanuela

AU - Fumagalli, Alessandra

AU - Mamone, Mario

AU - Savarino, Vincenzo

AU - Testa, Roberto

PY - 2005/7

Y1 - 2005/7

N2 - Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.

AB - Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.

KW - C-aminopyrine breath test

KW - Clarithromycin

KW - Helicobacter pylori

KW - Liver function

KW - Metronidazole

KW - Rabeprazole

UR - http://www.scopus.com/inward/record.url?scp=23044463770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044463770&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-2761-z

DO - 10.1007/s10620-005-2761-z

M3 - Article

C2 - 16047461

AN - SCOPUS:23044463770

VL - 50

SP - 1207

EP - 1213

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 7

ER -